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Introduction
The delayed, ineffective management of acute ischemic
stroke result in high rates of morbidity and mortality. For
patients with acute ischemic stroke who present with serious
neurologic symptoms on admission or continue to
deteriorate neurologically due to total occlusion despite
maximal medical treatment, an effective intervention to
improve their neurologic symptoms and clinical outcome has
not yet been established. 
Bone marrow (BM) or mobilized peripheral blood-driven
stem cell implants have been reported to regenerate damaged
brain tissues.7)19)30) BM-derived stem cells have been shown to
differentiate in in vitro cultures into neurons.7) Similarly,
they were reported to regenerate ischemic brain in vivo.30)
Data obtained on human CD34+ BM cells, show that
systemically administered CD34+ cells migrate to the site of
damage where they contribute to healing in the rat.8) These
observations aroused many hopes for the development of
new therapeutic strategies to ameliorate neurological deficits
in patients after stroke. 
The potential role of BM-derived progenitor/stem cells in
the regeneration of damaged tissue, however, is not clear at
this point. Generally, the beneficial effect of these cells in
regeneration could be explained by (1) trans-
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dedifferentiation/plasticity of hematopoietic stem cells,3)9)17)
(2) paracrine secretion of angiopoietic factors from BM-
derived stem/progenitor cells which improve vascularization
of the damaged organ, or (3) the presence of a heterogeneous
population of tissue-committed stem cells in the BM.14) 
The progenitor/stem-enriched CD34+ cells could be
mobilized into peripheral blood by administration of growth
factors (e.g. G-CSF), or chemotherapeutics (e.g.
cyclophosphamide), or a combination of them.5)23) The
expression of the CD34 surface antigen characterizes a
heterogeneous population of cells including hematopoietic
progenitor cells (HPCs), endothelial progenitor cells (EPCs),
and mature endothelial cells. Although the true role of the
CD34 molecule continues to be debated, CD34+ HSPC have
been functionally defined as capable of generating
progenitor-derived clones in vitro and by their potential in
reconstituting the lymphomyelopoietic system in
myelocompromised hosts.4)18)28) There are no data so far on
mobilization of these cells after ischemic stroke. 
The aim of this study was to evaluate the short-term
efficiency afte stereotactically injection of G-CSF-mobilized
hematopoietic CD34+ stem cells on peripheral bood in
patients with ischemic or hemorrhagic strokes with severe
neurological deficits. Additionally, we assessed VEGF levels
in CSF for the neurogenic and angiogenic capacity after the
stroke attack.
Patients and Methods
Patients
Approval was granted from our institutional review board
to study hematopoietic CD34+ stem cells transplantation as a
treatment for acute stroke with severe disabilities. From June
2004 to June 2005, we identified 5 patients who underwent
G-CSF-mobilized hematopoietic CD34+ stem cells
transplantation (Table 1). Two patients with acute middle
cerebral artery (MCA) occlusion were eligible for the study
if they had the following characteristics: (1) they had been
observed within 7 days of the onset of symptoms; (2) they
were relevant lesions within the MCA territory as assessed
using diffusion-weighted imaging; and (3) they had
experienced severely disabling deficits that persisted for
longer than 7 days (according to the National Institutes of
Health Stroke Scale [NIHSS], a score of 7 or more points
after 7 days of admission is severe) regardless the
conventional stroke treatment. Three patients with deep
intracerebral hemorrhage were eligible for the study if they
had the following characteristics: (1) they had severe
neurologic motor deficit (NIH motor scale, a score of 2 or
less points is severe); (2) they were relevant lesions with
non-visualization of posterior internal capsule (PIC) as
assessed using diffusion-tensor imaging; and (3) they had
experienced severely disabling deficits that persisted for
longer than 5 days regardless the stereotactic evacuation of
the hemorrhage. We excluded patients who met one of the
following criteria: hematological cause of stroke, severe co-
mobidity, hepatic or renal dysfunction, or unwillingness to
participate. Informed consent was obtained from patients or
medical guardians.
Mobilization and Collection of peripheral blood
hematopoietic stem cells
10 μg/kg of recombinant human granulocyte-colony-
stimulating factor (G-CSF) was administered subcutaneously
every 24 hours for 5 days. Since the previous study on
subcutaneous administration of G-CSF, peripheral blood
CD34+ levels reached near maximum after 4 days of G-CSF
treatment,19) we colleted peripheral blood stem cells on the
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Table 1. Summary of characteristics of patients with G-CSF mobilized peripheral blood hematopoietic CD34+ cells transplantation
Case
Age(yrs)/
Stroke
Location NIHSS at NIHSS 14 days NIHSS 1 month NIHSS 6 months
Sex of lesion admission posttransplantation posttransplantation posttransplantation
1 62/F Ischemic MCA territory 18 16 15 14
2 58/F Hemorrhagic Thalamus 14 14 13 14
3 064/M Hemorrhagic Thalamus 15 12 10 07
4 070/M Ischemic MCA territory 19 17 17 15
5 55/F Hemorrhagic Thalamus 16 15 13 12
G-CSF: Granulocyte-colony stimulating factor, NIHSS: National Institutes of Health Stroke Scale, MCA: middle cerebral artery
day following the fourth dose of G-CSF. The total blood
volume processed per apheresis was three times the donor’s
blood volume at flow rates of 70~80 ml/min. Whole blood:
anticoagulant ratio was programmed and anticoagulant
citrate dextrose solution (ACD-A) was used as an
anticoagulant. Total CD34+ cells were assayed according to
the International Society of Hematotherapy and Graft
Engineering (ISHAGE) guideline.21) The target dose of
CD34+ cell/kg was a maximum of 4×106/kg of patients.
Daily collection was performed to reach the target dose. 
Immunophenotyping
Peripheral blood mononuclear cells (MNC) were isolated
by standard Ficoll-Hypaque (Amersham Biosciences,
Uppsala, Sweden; density, 1.077 g/ml) density gradient
centrifugation. Isolated cell preparations (1×106 MNC)
were incubated for 30 min at 4℃ in the dark with
fluorescein isothiocyanate (FITC)-conjugated anti-CD34
(HPCA-2; Becton Dickinson, San Jose, CA, USA). As
isotype controls for the staining, we used FITC-conjugated
mouse immunoglobulin G1. Phenotypic analysis of CD34+
cells was performed with a FACS Calibur flow cytometer
(Becton Dickinson, Rutherford, NJ) equipped with a 15-mW
air-cooled argon-ion laser tuned at 488nm. Cell Quest
software was used for data acquisition and analysis (Fig. 1). 
Cells transplantation
On the day of injection, a MRI with axial slices of 5 mm
for calculation of the trajectory was performed. Targets were
located at the ischemic penumbra zone or perihematoma
zone (Fig. 2). Patients were then transferred to the operating
room and were placed on the Leksell stereotactic frame
(Elekta Instruments, Stockholm, Sweden). Catheter was
stereotactically inserted to target site. 5×106 cells were
injected to the target sites.
Measurement of improvements
The NIHSS score as an index of neurological deficit were
administered at regular intervals for up to 6 months after the
cell transplantation. Serial MRI was performed at 1 month
and 6 months after the cell transplantation. For assessing
VEGF levels in CSF, we obtained CSF by lumbar tab at
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Fig. 1. Representative study of flow-cytometry measurements of
the number of CD34+ cells in peripheral blood by use of
fluorescein isothiocyanate-conjugated anti-CD34 monoclonal
antibodies. 
Fig. 2. Case 1 with acute middle cerebral artery occlusion. A : Pretransplantation T2-weighted axial image. B : Localization of target
sites and calculation of the trajectory. C : Posttransplantation T2-weighted axial image. Arrow means the transplanted target site. 
Quadrant Statistics
File: 051001.004
Quad Events %Gated %Total
UL 0 0.00 0.00
UR 12 0.50 0.22
LL 257 10.64 4.61
LR 2147 88.87 38.48
regular intervals (every week) for up to 1 month. ELISA for
VEGF was performed using commercially available kits R &
D Systems. 
Statistical analysis
Difference between the final NIHSS score and the final
VEGF concentration in CSF was examined using Fisher’s
exact test. Statistical significance was established at p<0.05. 
Results
Clinical, laborato
y, radiographic evaluations of the G-CSF mobilized
hematopoietic CD34+ stem cells-treated patients showed no
deaths, stroke recurrence, or cell-related serious adverse
reactions. There was no immediate or delayed toxicity
related to stereotactic injection of stem cells during the
follow-up periods.
The mean NIHSS score was 16.4±2.1 at admission, 14.8
±1.9 at 14 days posttransplantation, 13.6±2.6 at 1 month
posttransplantation, and 12.4± 3.2 at 6 months
posttransplantation, respectively (Fig. 3). The VEGF
concentration in CSF was 4.6±2.4 pg/ml as basal levels,
24.0±6.7 pg/ml at 7 days posttransplantation, 48.2±17.2
pg/ml at 14 days posttransplantation, 49.0±15.6 pg/ml at 21
days posttransplantation, and 58.4±17.3 pg/ml at 28 days
posttransplantation, respectively (Fig. 4). Difference
between the final NIHSS score and the final VEGF
concentration in CSF was significant (p value=0.048). 
Discussion
This present data provide the first evidence that increased
VEGF concentration in CSF is strongly correlated with
improved neurological outcome in patients with with G-CSF
mobilized peripheral blood hematopoietic CD34+ cells
transplantation. However, it is controversial whether
spontaneous elevation of VEGF concentration after stroke
attack or stimulating effect of exogenous stem cells
transplantation was the cause for these unexpected
outcomes. 
Both global forebrain ischemia and focal ischemia, or
MCA occlusion, have been shown to induce neurogenesis in
the dentate gyrus in adult mammals.1)6)29) Studies in intact
animals provide evidence that various molecules can
enhance the intrinsic neurogenic capacity and thus might be
suitable to promote neuronal replacement following
ischemic events in the CNS. Vascular endothelial growth
factor (VEGF) elicits a delayed response on neurogenesis
following MCA occlusion in rats, which is attributed to a
survival rather than a proliferation effect.20) Reduction o
infarct volume and functional recovery point to an additional
neuroprotective effect exerted by VEGF. Interestingly,
brain-derived neurotrophic factor (BDNF), which enhances
neurogenesis in intact animals, decreases neurogenesis in a
global ischemia model following adeno-associated virus-
mediated BDNF overexpression in the hippocampus.10)
Further analysis indicates that these effects are at least
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Fig. 3. The National Institutes of Health Stroke Scales of five
patients with G-CSF mobilized peripheral blood hematopoietic
CD34+ cells transplantation. 
Fig. 4. VEGF concentration in cerebrospinal fluid of five patients
with G-CSF mobilized peripheral blood hematopoietic CD34+
cells transplantation. 
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partially mediated through upregulation of VEGF and BDNF
expression. None of the above-mentioned experiments can
clearly attribute the observed functional benefit to the
therapeutic agents induced effects on neurogenesis. 
The rationale to transplant stem cells into the damaged
brain is primarily to reconstruct the destroyed neuronal
circuit. In addition, cell grafts may exert a neuroprotective
effect by secreting survival promoting neurotrophic factors
either intrinsically or after introduction of therapeutic
transgenes. Very few clinical data are available regarding
adult stem cells transplantation in stroke patients. Only one
clinical study investigated the effects of autologous
mesenchymal stem cell (MSC) transplantation in patients
with severe cerebral infarcts.2) Serial evaluations showed no
adverse cell-related, serological, or imaging-defined effects.
The intravenous infusion of autologous MSCs appears to be
a feasible and safe therapy that may improve functional
recovery. However, the fate of the transplanted MSCs is
unknown; there have been rarely reported about MSCs
related to tumorigenesis.16)25)
The discovery that hematopoietic stem cells are capable of
transdifferentiating into neural lineages,13) together with the
accessibility of hematopoietic stem cells has shifted the
focus of attention into the application of hematopoietic stem
cells as a promising cell replacement strategy in the diseased
CNS. Subsequently, convincing evidence accumulated,
which questioned the occurrence of transdifferentiation.
Recent studies discovered that the phenomenon of cell
fusion and procedural artifacts in determining cell fate
account for the expression of neural lineage markers rather
than true transdifferentiation.11)24)27) Nevertheless, a vast
number of preclinical studies were conducted investigating
the regenerative capacity of hematopoietic stem cells
following brain damage either by mobilization of intrinsic
pools or by transplantation of hematopoietic stem cells.15)
Various sources of hematopoietic stem cells have been
used for preclinical studies: bone marrow stromal cells,
umbilical cord blood cells and G-CSF mobilized peripheral
blood cells (CD34+ cells). The number of hematopoietic
stem cells in the peripheral blood can be increased by
mobilizing cells from the bone marrow using G-CSF, thus
serving as an effective source for autologous hematopoietic
stem cells transplantation. Isolating hematopoietic stem cells
from peripheral blood can be performed without risk or
potential side effects. The first preclinical data suggest that
peripheral blood derived hematopoietic stem cells are as
efficient as umbilical cord blood derived hematopoietic stem
cells in promoting functional improvement following MCA
occlusion and intravenous transplantation in rats.26) 
We are aware that at this point it is still premature to
speculate on the biological function of mobilized
hematopoietic stem cells for acute stroke. First, these cells
may accompany mobilization of other more primitive
hematopoietic and non-hematopoietic stem cells (e.g.
endothelial, neural stem cells) that are mobilized into
peripheral blood in an attempt to regenerate brain directly.
Secondary, hematopoietic CD34+ stem cells are a rich source
of several proangiopoietic factors.12) Thus, it is possible that
they may home to the damaged tissue and by secreting
aniopoietic factors contribute to neovascularization. These
possibilities will be tested in our investigations.
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